Connections Chart
Multi-company connection
Former connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Nick Glover | M | 55 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 10 years |
Mary Christina Thomson | F | 53 | 2 years | |
Nicole Onetto | M | 71 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 years |
Robert E. Pelzer | M | 70 | 7 years | |
Justin T. Huang | M | - | - | |
Stephen Dilly | M | 64 | 2 years | |
Andrew Sinclair | M | 52 | 3 years | |
Georgia Erbez | F | 57 | 1 years | |
Christy Oliger | F | 54 | 1 years | |
Barbara Klencke | M | 66 | 7 years | |
Philip Frost | M | 84 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 years |
Tryon Williams | M | 84 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 17 years |
Daniel J. Estes | M | 43 | 2 years | |
Gregg Smith | M | - |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 7 years |
Alvin Vitangcol | M | 49 | 3 years | |
Kapil Dhingra | M | 64 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 1 years |
Jeffrey Cooper | M | 68 | 6 years | |
Andrew Allen | M | 57 | 5 years | |
Wendi V. Rodrigueza | M | 58 | 10 years | |
Emma McCann | F | - | 8 years | |
Tran Nguyen | M | 50 | 3 years | |
Donald Parfet | M | 71 | 4 years | |
Albert Cha | M | 51 | 2 years | |
James Topper | M | 62 | 3 years | |
Peter Thompson | M | 64 | 1 years | |
Craig Collard | M | 58 | 2 years | |
François Thomas | M | 66 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 5 years |
Gaurav Aggarwal | M | 51 | 3 years | |
Mona Ashiya | M | 55 | 3 years | |
Catherine Mackey | M | 68 |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 years |
Kevin Thomas Ryan | M | - | - | |
Diane Gardiner | F | - | - | |
Josh Richardson | M | 42 | 3 years | |
Christian Hassig | M | 52 | - | |
Amy Barrier Altshul | F | - | - | |
Kevin Norrett | M | 51 | 2 years | |
Simon Eastman | M | - | - | |
Lauren Rose Musto | F | - | 1 years | |
Keith E. Anderson | M | 55 | 7 years | |
Sukhi Jagpal | M | 50 | 7 years | |
Wendy Chapman | F | 58 | 8 years | |
Denis G. Bosc | M | - |
YM BioSciences, Inc.
YM BioSciences, Inc. Pharmaceuticals: MajorHealth Technology YM BioSciences, Inc. operates as a drug development company, which manufactures advancing hematology and cancer-related products. It is currently advancing in late-stage products, which include CYT387, an oral small molecule inhibitor of the kinase enzymes JAK1 and JAK2; and Nimotuzumab, an EGFR targeting humanized monoclonal antibody. The company was founded in 1994 and is headquartered in Mississauga, Canada. | 2 years |
Chandra D. Lovejoy | F | 52 | 3 years | |
Mark Kowalski | M | 69 | 5 years | |
William D. Turner | M | 58 | 2 years | |
Angie You | M | 51 | 4 years | |
Richard A. Messmann | M | 67 | 4 years | |
Alexandra Marie Nieves Gonzalez | F | - | - |
Statistics
Country | Connections | % of total |
---|---|---|
United States | 42 | 87.50% |
United Kingdom | 9 | 18.75% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- James Smith
- Personal Network